Trials / Unknown
UnknownNCT05301465
Predictive Role of Circulating Angiogenic Factors for Second-line Paclitaxel and Ramucirumab.
Prospective Study to Identify and Validate the Predictive Role of Circulating Angiogenic Factors in Patients With Metastatic Gastric Cancer Treated With Second-line Paclitaxel and Ramucirumab
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- University of Pisa · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The project is primarily aimed at identifying and subsequently validating the predictive role of plasma concentrations of VEGF-A (vascular endothelial growth factor A), VEGF-D (vascular endothelial growth factor D) and s-VEGFR2 (soluble Vascular Endothelial Growth Factor Receptor 2) measured prior to initiation and during second-line treatment with paclitaxel and ramucirumab in patients with unresectable gastric cancer pretreated with first-line chemotherapy. For the primary endpoint, the efficacy parameter chosen is PFS, calculated from day 1 of treatment to date of progression or death.
Conditions
Timeline
- Start date
- 2021-11-01
- Primary completion
- 2022-11-01
- Completion
- 2023-06-01
- First posted
- 2022-03-29
- Last updated
- 2022-03-29
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT05301465. Inclusion in this directory is not an endorsement.